Opportunities to Optimize Cancer Policies Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Welcome and Introduction to Vi3C

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Oct

Today In Oncology

Opportunities to Optimize Cancer Policies Panel Discussion

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Welcome and Introduction to Vi3C

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy

FDA Approves First-Line Pirtobrutinib for CLL-SLL

FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma

FDA Approves New Labeling of ROS1 Inhibitor for NSCLC

Charles Perou 2026 William L. McGuire Memorial Lecture Award